Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy

Domínguez-Ríos, Rossina; Sánchez-Ramírez, Dante R.; Ruiz-Saray, Kassandra; Oceguera-Basurto, Paola E.; Almada, Mario; Juárez, Josué; Zepeda‐Moreno, Abraham; Toro-Arreola, Alicia del; Topete, Antonio; Daneri-Navarro, ́Adrián

doi:10.1016/j.colsurfb.2019.03.011

Cited by 71 publications

(38 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quantitative analysis of PET images was performed using the same method as previously reported. [32,33] Biodistribution Mice were injected with 0.74 MBq of the tracer via the tail vein and sacrificed at 1,4,8,18,24,48 and 72 hour after administration respectively. For a blocking study, four mice were coinjected with an excess of unlabeled Cys-ZHER 2:342 (10mg/kg body weight) and killed at 1 hour after administration.…”

Section: Micropet Imagingmentioning

confidence: 99%

See 1 more Smart Citation

Synthesize of a novel 89Zr labeled HER2 affibody and its application study in tumor PET imaging

Xu¹,

Wang²,

Pan³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Human epidermal growth factor receptor-2 (HER2) is an important biomarker for tumor diagnosis and therapy. Affibody is an ideal vector for preparing HER2 specific probes due to the advantages such as high affinity and rapid blood clearance etc. 89Zr is a novel PET imaging isotope with long half-lives and suitable for tracking biological processes for longer periods. In this study, a novel 89Zr labeled HER2 affibody, 89Zr-DFO-MAL-Cys-MZHER2, was synthesized and its imaging properties were also evaluated. Results: The precursors, DFO-MAL-Cys-MZHER2, were obtained with the yields of nearly 50%. The yields of 89Zr -DFO-MAL-Cys-MZHER2 were 90.2±1.9% and the radiopurities were more than 95%. The total synthesis time was only 30 minutes. The probes were stable in PBS and serum. The tracer accumulated in HER2 overexpression human ovarian cancer SKOV-3 cells. In vivo studies in mice bearing tumors showed that the probe highly retained in SKOV-3 xenografts even for 48 hours. The tumors were visualized with good contrast to normal tissue. ROI analysis revealed that the average uptakes in the tumor were greater than 5 %ID/g. On the contrary, the counterparts of MCF-7 tumors kept low levels of （~1%ID/g）. The outcome was consistent with the immunohistochemical analysis and ex vivo autoradiography. The probe quickly cleared from the blood and normal organs, and mainly excreted through the urinary system. Conclusion: The novel HER2 affibody for PET imaging was easily prepared with satisfactory labeling yield and radiochemical purity. 89Zr-DFO-MAL-MZHER is a potential candidate for monitoring HER2 expression and may play specific roles in clinical cancer theranostics.

show abstract

Section: Micropet Imagingmentioning

confidence: 99%

“…Overexpression of HER2 was found in various solid tumors including ovarian, breast, lung, gastric, colon cancers, etc and associated with aggressiveness, recurrence, and poor survival. [2][3][4] Thus, HER2 is an important clinical tumor biomarker and therapeutic target.…”

Section: Introductionmentioning

confidence: 99%

Synthesize of a novel 89Zr labeled HER2 affibody and its application study in tumor PET imaging

Xu¹,

Wang²,

Pan³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…HER2 is an essential clinical tumor biomarker since it is overexpressed in various solid tumors, including ovarian, gastric, and breast cancers. Also, abundant expression of the receptor is associated with aggressiveness, recurrence, and reduced survival [2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Synthesis of a novel 89Zr-labeled HER2 affibody and its application study in tumor PET imaging

Wang

Pan

et al. 2020

EJNMMI Res

View full text Add to dashboard Cite

Background: Human epidermal growth factor receptor-2 (HER2) is an essential biomarker for tumor treatment. Affibody is an ideal vector for preparing HER2 specific probes because of high affinity and rapid clearance from normal tissues, etc. Zirconium-89 is a PET imaging isotope with a long half-life and suitable for monitoring biological processes for more extended periods. In this study, a novel 89 Zr-labeled HER2 affibody, [ 89 Zr]Zr-DFO-MAL-Cys-MZHER2, was synthesized, and its imaging characters were also assessed. Results: The precursor, DFO-MAL-Cys-MZHER2, was obtained with a yield of nearly 50%. The radiochemical yield of [ 89 Zr]Zr-DFO-MAL-Cys-MZHER2 was 90.2 ± 1.9%, and the radiochemical purity was higher than 95%. The total synthesis time was only 30 min. The probe was stable in PBS and serum. The tracer accumulated in HER2 overexpressing human ovarian cancer SKOV-3 cells. In vivo studies in mice bearing tumors showed that the probe was highly retained in SKOV-3 xenografts even for 48 h. The tumors were visualized with good contrast to normal tissues. ROI analysis revealed that the average uptake values in the tumor were greater than 5% IA/g during 48 h postinjection. On the contrary, the counterparts of MCF-7 tumors kept low levels (~1% IA/g). The outcome was consistent with the immunohistochemical analysis and ex vivo autoradiography. The probe quickly cleared from the normal organs except kidneys and mainly excreted through the urinary system. Conclusion: The novel HER2 affibody for PET imaging was easily prepared with satisfactory labeling yield and radiochemical purity. [ 89 Zr]Zr-DFO-MAL-Cys-MZHER2 is a potential candidate for detecting HER2 expression. It may play specific roles in clinical cancer theranostics.

show abstract

“…HER2 is an essential clinical tumor biomarker since it is overexpressed in various solid tumors, including ovarian, gastric, breast cancers, etc and associated with aggressiveness, recurrence, and reduced survival. [2][3][4] Monoclonal antibodies, including trastuzumab and pertuzumab etc have been used for therapy of HER2-positive cancers. [5][6][7] Current selection of patients for targeted therapy is mainly dependent on the status of HER2, which was determined by biopsy using immunohistochemistry or uorescence in situ hybridization.…”

Section: Introductionmentioning

confidence: 99%

Synthesis of a novel 89Zr labeled HER2 affibody and its application study in tumor PET imaging

Xu¹,

Wang²,

Pan³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Human epidermal growth factor receptor-2 (HER2) is an essential biomarker for tumor treatment. Affibody is an ideal vector for preparing HER2 specific probes because of high affinity and rapid clearance from normal tissues etc. Zirconium-89 is a PET imaging isotope with a long half-life and suitable for monitoring biological processes for more extended periods. In this study, a novel 89Zr-labeled HER2 affibody, [89Zr]Zr-DFO-MAL-Cys-MZHER2, was synthesized, and its imaging characters were also assessed. Results: The precursor, DFO-MAL-Cys-MZHER2, was obtained with a yield of nearly 50%. The radiochemical yield of [89Zr]Zr -DFO-MAL-Cys-MZHER2 was 90.2±1.9% , and the radiochemical purity was higher than 95%. The total synthesis time was only 30 minutes. The probe was stable in PBS and serum. The tracer accumulated in HER2 overexpressing human ovarian cancer SKOV-3 cells. In vivo studies in mice bearing tumors showed that the probe highly retained in SKOV-3 xenografts even for 48 hours. The tumors were visualized with good contrast to normal tissues. ROI analysis revealed that the average uptake values in the tumor were greater than 5%IA/g during 48 hours postinjection. On the contrary, the counterparts of MCF-7 tumors kept low levels（~1%IA/g）. The outcome was consistent with the immunohistochemical analysis and ex vivo autoradiography. The probe quickly cleared from the normal organs except kidneys and mainly excreted through the urinary system. Conclusion: The novel HER2 affibody for PET imaging was easily prepared with satisfactory labeling yield and radiochemical purity. [89Zr]Zr-DFO-MAL-Cys-MZHER2 is a potential candidate for detecting HER2 expression. It may play specific roles in clinical cancer theranostics.

show abstract

Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy

Cited by 71 publications

References 49 publications

Synthesize of a novel 89Zr labeled HER2 affibody and its application study in tumor PET imaging

Synthesize of a novel 89Zr labeled HER2 affibody and its application study in tumor PET imaging

Synthesis of a novel 89Zr-labeled HER2 affibody and its application study in tumor PET imaging

Synthesis of a novel 89Zr labeled HER2 affibody and its application study in tumor PET imaging

Contact Info

Product

Resources

About